Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients.
Antineoplastic Agents, Immunological
/ pharmacology
Biomarkers, Tumor
/ antagonists & inhibitors
Breast
/ immunology
Breast Neoplasms
/ genetics
Datasets as Topic
Female
Ferroptosis
/ drug effects
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Kaplan-Meier Estimate
Middle Aged
Predictive Value of Tests
Prognosis
Protein Interaction Maps
/ drug effects
ROC Curve
Risk Assessment
/ methods
Breast cancer
Ferroptosis
Immune status
Prognostic signature
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
31 May 2021
31 May 2021
Historique:
received:
29
10
2020
accepted:
11
05
2021
entrez:
1
6
2021
pubmed:
2
6
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Breast cancer (BRCA) is a malignant tumor with high morbidity and mortality, which is a threat to women's health worldwide. Ferroptosis is closely related to the occurrence and development of breast cancer. Here, we aimed to establish a ferroptosis-related prognostic gene signature for predicting patients' survival. Gene expression profile and corresponding clinical information of patients from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database. The Least absolute shrinkage and selection operator (LASSO)-penalized Cox regression analysis model was utilized to construct a multigene signature. The Kaplan-Meier (K-M) and Receiver Operating Characteristic (ROC) curves were plotted to validate the predictive effect of the prognostic signature. Gene Ontology (GO) and Kyoto Encyclopedia of Genes, Genomes (KEGG) pathway and single-sample gene set enrichment analysis (ssGSEA) were performed for patients between the high-risk and low-risk groups divided by the median value of risk score. We constructed a prognostic signature consisted of nine ferroptosis-related genes (ALOX15, CISD1, CS, GCLC, GPX4, SLC7A11, EMC2, G6PD and ACSF2). The Kaplan-Meier curves validated the fine predictive accuracy of the prognostic signature (p < 0.001). The area under the curve (AUC) of the ROC curves manifested that the ferroptosis-related signature had moderate predictive power. GO and KEGG functional analysis revealed that immune-related responses were largely enriched, and immune cells, including activated dendritic cells (aDCs), dendritic cells (DCs), T-helper 1 (Th1), were higher in high-risk groups (p < 0.001). Oppositely, type I IFN response and type II IFN response were lower in high-risk groups (p < 0.001). Our study indicated that the ferroptosis-related prognostic signature gene could serve as a novel biomarker for predicting breast cancer patients' prognosis. Furthermore, we found that immunotherapy might play a vital role in therapeutic schedule based on the level and difference of immune-related cells and pathways in different risk groups for breast cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer (BRCA) is a malignant tumor with high morbidity and mortality, which is a threat to women's health worldwide. Ferroptosis is closely related to the occurrence and development of breast cancer. Here, we aimed to establish a ferroptosis-related prognostic gene signature for predicting patients' survival.
METHODS
METHODS
Gene expression profile and corresponding clinical information of patients from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database. The Least absolute shrinkage and selection operator (LASSO)-penalized Cox regression analysis model was utilized to construct a multigene signature. The Kaplan-Meier (K-M) and Receiver Operating Characteristic (ROC) curves were plotted to validate the predictive effect of the prognostic signature. Gene Ontology (GO) and Kyoto Encyclopedia of Genes, Genomes (KEGG) pathway and single-sample gene set enrichment analysis (ssGSEA) were performed for patients between the high-risk and low-risk groups divided by the median value of risk score.
RESULTS
RESULTS
We constructed a prognostic signature consisted of nine ferroptosis-related genes (ALOX15, CISD1, CS, GCLC, GPX4, SLC7A11, EMC2, G6PD and ACSF2). The Kaplan-Meier curves validated the fine predictive accuracy of the prognostic signature (p < 0.001). The area under the curve (AUC) of the ROC curves manifested that the ferroptosis-related signature had moderate predictive power. GO and KEGG functional analysis revealed that immune-related responses were largely enriched, and immune cells, including activated dendritic cells (aDCs), dendritic cells (DCs), T-helper 1 (Th1), were higher in high-risk groups (p < 0.001). Oppositely, type I IFN response and type II IFN response were lower in high-risk groups (p < 0.001).
CONCLUSION
CONCLUSIONS
Our study indicated that the ferroptosis-related prognostic signature gene could serve as a novel biomarker for predicting breast cancer patients' prognosis. Furthermore, we found that immunotherapy might play a vital role in therapeutic schedule based on the level and difference of immune-related cells and pathways in different risk groups for breast cancer patients.
Identifiants
pubmed: 34059009
doi: 10.1186/s12885-021-08341-2
pii: 10.1186/s12885-021-08341-2
pmc: PMC8165796
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
645Subventions
Organisme : National Natural Science Foundation of China
ID : 81974049
Références
Clin Cancer Res. 2018 Feb 1;24(3):511-520
pubmed: 28801472
Adv Cancer Res. 2019;143:295-349
pubmed: 31202361
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cell Cycle. 2012 Nov 15;11(22):4174-80
pubmed: 23070475
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14676-81
pubmed: 23959881
Expert Rev Mol Diagn. 2019 Nov;19(11):979-995
pubmed: 31594418
Biomark Res. 2020 Nov 5;8(1):58
pubmed: 33292585
Int J Biol Sci. 2020 Jul 6;16(13):2430-2441
pubmed: 32760210
PLoS One. 2017 Aug 21;12(8):e0182921
pubmed: 28827805
J Clin Invest. 2011 May;121(5):2000-12
pubmed: 21540548
Sci Rep. 2017 Jun 19;7(1):3791
pubmed: 28630426
Cell Death Dis. 2016 Jul 21;7:e2307
pubmed: 27441659
Nat Chem Biol. 2017 Jan;13(1):91-98
pubmed: 27842070
Cancer Discov. 2015 Sep;5(9):915-9
pubmed: 26272491
Free Radic Biol Med. 2019 Mar;133:144-152
pubmed: 30219704
Biochem Biophys Res Commun. 2021 Jun 18;558:216-223
pubmed: 33008584
Mol Cell Biochem. 2020 Oct;473(1-2):217-228
pubmed: 32642794
Biomark Res. 2020 Oct 2;8:50
pubmed: 33024562
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
BMC Cancer. 2018 May 11;18(1):556
pubmed: 29751789
J Cell Mol Med. 2020 Jun;24(11):6242-6252
pubmed: 32307830
Sci Rep. 2019 Mar 7;9(1):3788
pubmed: 30846710
Chem Res Toxicol. 2011 Aug 15;24(8):1231-41
pubmed: 21728338
J Exp Clin Cancer Res. 2019 Apr 12;38(1):160
pubmed: 30987650
Front Pharmacol. 2019 Oct 31;10:1226
pubmed: 31736748